跳至主要内容
临床试验/DRKS00031821
DRKS00031821已完成Unknown

Evaluation of the pharmacokinetics of caffeine, baicalin, baicalein, and sulfasalazine after oral administration

Institut für Pharmazie; Biopharmazie & Pharmazeutische Technologie0 个研究点目标入组 12 人开始时间: 2023年5月8日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 55 Years(—)
性别
All

入选标准

  • BMI: >= 18 kg/m² and <= 30 kg/m²
  • Minimum weight: 50 kg
  • Good health, which has been clinically evaluated to be normal by the responsible study physician
  • Complete immunisation against SARS-Cov2
  • Written consent form

排除标准

  • - Disorders/diseases that affect the swallowing process (e.g., severe dysphagia related to food and/or solid oral dosage forms)
  • - Gastrointestinal disease and/or pathologic changes that may interfere with gastric emptying
  • - Known or suspected stenosis, fistula, or mechanical obstruction within the gastrointestinal tract
  • - Surgical procedures on the gastrointestinal tract within the past 12 months
  • - Inflammatory bowel disease (Crohn's disease, ulcerative colitis or diverticulitis)
  • - Known allergies or intolerances to any components of the standard meal or administered vehicles (especially caffeine, sulfasalazine, baicalin, mannitol, silica)
  • - alcohol or drug dependence
  • - Smokers with a cigarette consumption of more than 10 cigarettes per day
  • - Heavy tea or coffee drinkers (more than 1 L per day)
  • - Eating disorders such as anorexia, bulimia in the last 12 months
  • - Individuals with dietary habits that affect gastrointestinal motility (e.g., vegans, strict fasting)
  • - Positive pregnancy test or gravidity
  • - Breastfeeding
  • - Positive SARS-Cov 2 antigen rapid test or PCR test
  • - Individuals known to be unwilling or unable to reliably follow instructions
  • - Individuals who are unable to understand written and verbal instructions and teachings regarding the study risks they face
  • - Less than 14 days of acute illness
  • - Systemic use of medications, especially those that affect gastrointestinal tract function
  • - Taking antibiotics in the past 3 months
  • - Whole blood donation in the last 4 weeks
  • - Anemia (hemoglobin < 13 g/dL (8.07 mmol/L) in males or
  • < 12 g/dL (7.45 mmol/L) in female subjects).
  • - Increased liver function values (ALAT, ASAT, ?GT, bilirubin <2x ULN).
  • - Reduced renal function (eGFR MDRD < 60 mL/min/1.7 m 2 )
  • - Poor venous conditions that do not allow peripheral venous catheter to be placed and blood to be drawn regularly through it
  • No medications should be taken during the study and for 4 weeks prior to it that affect gastrointestinal motility and gastric function. Deviations from
  • this rule are possible if at least 10 half-lives have elapsed between the last drug and the start of the study are at least 10 half-lives.
  • Drugs of concern include, but are not limited to:
  • - Laxatives
  • - Antidiarrheal agents
  • - Prokinetic antiemetics
  • - Drugs with pronounced anticholinergic effects such as neuroleptics and
  • Antidepressants
  • - Opioid analgesics
  • - antibiotics
  • - Antacids, proton pump inhibitors, H2 antihistamines
  • - calcium antagonists
  • - beta blockers
  • - Nitrates

研究者

发起方
Institut für Pharmazie; Biopharmazie & Pharmazeutische Technologie

相似试验

Evaluation of the pharmacokinetics of caffeine,... | 临床试验